Corneal Neovascularization (Ophthalmology) - Drugs In Development, 2021

August 2021 | 47 pages | ID: C666D8228E6EEN
Global Markets Direct

Abstracts

Corneal Neovascularization (Ophthalmology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Drugs In Development, 2021, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape.Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Corneal Neovascularization - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Corneal Neovascularization - Overview
Corneal Neovascularization - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Corneal Neovascularization - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Corneal Neovascularization - Companies Involved in Therapeutics Development
Chengdu Kanghong Pharmaceuticals Group Co Ltd
EyeGate Pharmaceuticals Inc
FortuneRock (China) Ltd
Gene Signal International SA
Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd
Singh Biotechnology LLC
Wntgen LLC
Corneal Neovascularization - Drug Profiles
aganirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Corneal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Raver-2 Protein for Ophthalmology Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit VEGF-A for Corneal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDE-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDR-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KH-906 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins for Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wnt-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Corneal Neovascularization - Dormant Projects
Corneal Neovascularization - Product Development Milestones
Featured News & Press Releases
Jan 10, 2017: Zaphyr Pharmaceuticals and gene signal enter into collaboration for GS-101 (Aganirsen) in the Middle East & North Africa region
May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation.
Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure
Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Corneal Neovascularization, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Corneal Neovascularization - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021
Corneal Neovascularization - Pipeline by EyeGate Pharmaceuticals Inc, 2021
Corneal Neovascularization - Pipeline by FortuneRock (China) Ltd, 2021
Corneal Neovascularization - Pipeline by Gene Signal International SA, 2021
Corneal Neovascularization - Pipeline by Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd, 2021
Corneal Neovascularization - Pipeline by Singh Biotechnology LLC, 2021
Corneal Neovascularization - Pipeline by Wntgen LLC, 2021
Corneal Neovascularization - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Corneal Neovascularization, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021